Advertisement

Ocular Therapeutix Inc., a Bedford developer of ophthalmic therapeutic products, has closed a Proof of Principle clinical study of its moxifloxacin punctum plug, a sustained drug delivery device for post-cataract surgery.

According to company officials, the study returned positive news in that the 10 patients all continued use of the plug in the study, and the plug succeeded in maintaining at least the minimum amount of moxifloxacin, an antibiotic, to prevent growth of bacterial conjunctivitis.

SOURCE

Advertisement
Advertisement